Program
Ambroxol
Also written as “Ambroxol Spray”, “Ambroxol Hydrochloride” and “Ambroxol hydrochloride (Mucoangin?)”.
Its studies are mostly in Pharyngitis · Gaucher Disease · Parkinson Disease, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boehringer Ingelheim | 30 open or running | phase 3since Sep 7, 2005 | Sep 7, 2005 | none ahead |
| Agyany Pharma | 20 open or running | phase 2since Nov 7, 2023 | Nov 7, 2023 | none ahead |
| Exsar | 10 open or running | phase 2since Oct 27, 2011 | Oct 27, 2011 | none ahead |
| Hanmi Pharmaceutical | 10 open or running | phase 1since Apr 5, 2012 | Apr 5, 2012 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 7, 2005First study: phase 3 study in PharyngitisNew to Boehringer IngelheimBoehringer Ingelheim · NCT00148499 · 751 enrolled · Romania, Ukraine
- Sep 3, 2007Phase 3 study in PharyngitisBoehringer Ingelheim · NCT00525044 · 249 enrolled · China
- May 16, 2011Phase 2 study in PharyngitisBoehringer Ingelheim · NCT01361802 · 494 enrolled · South Africa
- Oct 27, 2011Exsar's first study: phase 2 study in Gaucher DiseaseNew to ExsarExsar · NCT01463215 · 20 enrolled · United States
- Apr 5, 2012Hanmi Pharmaceutical's first study: phase 1 study in HealthyNew to Hanmi PharmaceuticalHanmi Pharmaceutical · NCT01573663 · 21 enrolled · Korea, Republic of
- Nov 7, 2023Agyany Pharma's first study: phase 2 study in Parkinson DiseaseNew to Agyany PharmaAgyany Pharma · NCT06193421 · 46 enrolled · Israel
- Nov 21, 2025No phase study in Gaucher DiseaseAgyany Pharma · NCT07285369 · 12 enrolled · Pakistan
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07285369Gaucher Disease · Pakistan | – | Completed | Agyany Pharma | Mar 30, 2026 | 12 |
| NCT06193421Parkinson Disease · Israel | 2 | Terminated | Agyany Pharma | Mar 30, 2026 | 46 |
| NCT01573663Healthy · Korea, Republic of | 1 | Completed | Hanmi Pharmaceutical | Apr 2012 | 21 |
| NCT01463215Gaucher Disease · United States | 2 | Suspended | Exsar | Dec 2014 | 20 |
| NCT01361802Pharyngitis · South Africa | 2 | Completed | Boehringer Ingelheim | Aug 2011 | 494 |
| NCT00525044Pharyngitis · China | 3 | Completed | Boehringer Ingelheim | Jan 1, 2008 | 249 |
| NCT00148499Pharyngitis · Romania, Ukraine | 3 | Completed | Boehringer Ingelheim | Jun 2006 | 751 |
How it is read
Names in the registry
- “Ambroxol”, 4 entries
- “Ambroxol Spray”, 3 entries
- “Ambroxol Hydrochloride”, 1 entry
- “Ambroxol hydrochloride (Mucoangin?)”, 1 entry
- “Ambroxol and Levodropropizine”, 1 entry
Conditions, from the studies’ own filings
- Pharyngitis, 3 studies
- Gaucher Disease, 2 studies
- Parkinson Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.